These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23922377)

  • 21. Correlates of protection for inactivated enterovirus 71 vaccine: the analysis of immunological surrogate endpoints.
    Zhu W; Jin P; Li JX; Zhu FC; Liu P
    Expert Rev Vaccines; 2017 Sep; 16(9):945-949. PubMed ID: 28548626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Similar protective immunity induced by an inactivated enterovirus 71 (EV71) vaccine in neonatal rhesus macaques and children.
    Zhang Y; Wang L; Liao Y; Liu L; Ma K; Yang E; Wang J; Che Y; Jiang L; Pu J; Guo L; Feng M; Liang Y; Cui W; Yang H; Li Q
    Vaccine; 2015 Nov; 33(46):6290-7. PubMed ID: 26419198
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles.
    Lin YL; Yu CI; Hu YC; Tsai TJ; Kuo YC; Chi WK; Lin AN; Chiang BL
    Vaccine; 2012 Feb; 30(7):1305-12. PubMed ID: 22214888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Two-year efficacy and immunogenicity of Sinovac Enterovirus 71 vaccine against hand, foot and mouth disease in children.
    Li JX; Song YF; Wang L; Zhang XF; Hu YS; Hu YM; Xia JL; Li J; Zhu FC
    Expert Rev Vaccines; 2016; 15(1):129-37. PubMed ID: 26460695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized, double-blind, placebo-controlled phase I clinical trial of rotavirus inactivated vaccine (Vero cell) in a healthy adult population aged 18-49 years to assess safety and preliminary observation of immunogenicity.
    Wu JY; Zhang W; Pu J; Liu Y; Huang LL; Zhou Y; Gao JM; Tan JB; Liu XL; Yang J; Lin XC; Feng GW; Yin N; Chen R; Hu XQ; Yi S; Ye J; Kuang XJ; Wang Y; Zhang GM; Sun MS; Wang YX; Hu ZY; Yang JS; Li HJ
    Vaccine; 2024 Jul; 42(19):4030-4039. PubMed ID: 38796326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunity and clinical efficacy of an inactivated enterovirus 71 vaccine in healthy Chinese children: a report of further observations.
    Liu L; Mo Z; Liang Z; Zhang Y; Li R; Ong KC; Wong KT; Yang E; Che Y; Wang J; Dong C; Feng M; Pu J; Wang L; Liao Y; Jiang L; Tan SH; David P; Huang T; Zhou Z; Wang X; Xia J; Guo L; Wang L; Xie Z; Cui W; Mao Q; Liang Y; Zhao H; Na R; Cui P; Shi H; Wang J; Li Q
    BMC Med; 2015 Sep; 13():226. PubMed ID: 26381232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
    Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
    Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical evaluation for batch consistency of an inactivated enterovirus 71 vaccine in a large-scale phase 3 clinical trial.
    Chen YJ; Meng FY; Mao Q; Li JX; Wang H; Liang ZL; Zhang YT; Gao F; Chen QH; Hu Y; Ge ZJ; Yao X; Guo HJ; Zhu FC; Li XL
    Hum Vaccin Immunother; 2014; 10(5):1366-72. PubMed ID: 24633366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study.
    Englund JA; Walter E; Black S; Blatter M; Nyberg J; Ruben FL; Decker MD;
    Pediatr Infect Dis J; 2010 Feb; 29(2):105-10. PubMed ID: 19934787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study.
    Omenaca F; Sarlangue J; Szenborn L; Nogueira M; Suryakiran PV; Smolenov IV; Han HH;
    Pediatr Infect Dis J; 2012 May; 31(5):487-93. PubMed ID: 22228231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children.
    Bernstein DI; Malkin E; Abughali N; Falloon J; Yi T; Dubovsky F;
    Pediatr Infect Dis J; 2012 Feb; 31(2):109-14. PubMed ID: 21926667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine.
    Cheng A; Fung CP; Liu CC; Lin YT; Tsai HY; Chang SC; Chou AH; Chang JY; Jiang RH; Hsieh YC; Su IJ; Chong PC; Hsieh SM
    Vaccine; 2013 May; 31(20):2471-6. PubMed ID: 23541623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term immunogenicity and safety of inactivated Hantaan virus vaccine (Hantavax™) in healthy adults.
    Song JY; Woo HJ; Cheong HJ; Noh JY; Baek LJ; Kim WJ
    Vaccine; 2016 Mar; 34(10):1289-95. PubMed ID: 26826547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2-11 years in Malaysia: a randomized, placebo-controlled, Phase III study.
    Hss AS; Koh MT; Tan KK; Chan LG; Zhou L; Bouckenooghe A; Crevat D; Hutagalung Y
    Vaccine; 2013 Dec; 31(49):5814-21. PubMed ID: 24135573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reactogenicity and immunogenicity of an enterovirus 71 vaccine in Chinese healthy children and infants.
    Zhu FC; Wang JZ; Li XL; Liang ZL; Ge HM; Meng FY; Mao QY; Zhang YT; Zhang ZY; Ji H; Gao F; Guo HJ; Zhu QY; Chu K; Wu X; Li JX; Chen QH; Chen XQ; Zhang WW; Hu YM; Li L; Li FX; Yao X; Liu P; Wang H; Shen XL
    Pediatr Infect Dis J; 2012 Nov; 31(11):1158-65. PubMed ID: 22926209
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparing the Primary and Recall Immune Response Induced by a New EV71 Vaccine Using Systems Biology Approaches.
    Shao J; Zhang J; Wu X; Mao Q; Chen P; Zhu F; Xu M; Kong W; Liang Z; Wang J
    PLoS One; 2015; 10(10):e0140515. PubMed ID: 26465882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial.
    Poland GA; Jacobson RM; Koutsky LA; Tamms GM; Railkar R; Smith JF; Bryan JT; Cavanaugh PF; Jansen KU; Barr E
    Mayo Clin Proc; 2005 May; 80(5):601-10. PubMed ID: 15887427
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
    Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
    J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influenza A (H1N1) 2009 two-dose immunization of US children: an observer-blinded, randomized, placebo-controlled trial.
    Plennevaux E; Blatter M; Cornish MJ; Go K; Kirby D; Wali M; Reeves-Hoché MK; Denis M
    Vaccine; 2011 Feb; 29(8):1569-75. PubMed ID: 21219979
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial.
    Nguyen TT; Chiu CH; Lin CY; Chiu NC; Chen PY; Le TTV; Le DN; Duong AH; Nguyen VL; Huynh TN; Truong HK; Phan TL; Nguyen TTT; Shih SR; Huang CG; Weng YJ; Hsieh EF; Chang S; Chen C; Tai IC; Huang LM
    Lancet; 2022 Apr; 399(10336):1708-1717. PubMed ID: 35427481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.